R&D Spotlight:
Next-Generation Drug Screening: AI, Automation & Human-Relevant Models
Next-Generation Drug Screening: AI, Automation & Human-Relevant Models
SPONSORED BY
Discover the latest technologies transforming drug screening, hit identification and early discovery.
Explore how AI, automation and human-relevant models are being integrated into screening workflows to accelerate hit identification, improve prioritisation and generate more predictive biological insights. This focused online showcase brings together industry experts to examine next-generation approaches including high-content and phenotypic screening, CRISPR functional genomics, organoids and organ-on-chip models.
- Accelerate Hit Identification – Explore AI-guided approaches for identifying, prioritising and advancing promising drug discovery hits
- Transform Screening Workflows – Gain insights into high-content and phenotypic screening, automation and CRISPR functional genomics for more efficient target and hit evaluation
- Increase Human Relevance – Explore organoids, organ-on-chip and other human-relevant models designed to improve the predictive value of screening approaches
VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:
- Drug Screening
- Hit Identification
- AI & Machine Learning
- High-Content Screening
- Phenotypic Screening
- Automation & Robotics
- CRISPR & Functional Genomics
- Organoid Research
- Organ-on-Chip
- Translational Research
60-Minute Agenda
Industry Presentation
Industry Presentation
Solution Provider Presentation
Panel Discussion
End of Technology Showcase
About 10x Genomics
10x Genomics builds technologies that turn biology into answers, giving researchers the resolution to see how diseases develop and respond to treatment.
Its Chromium Single Cell platform delivers single cell multiomics across thousands of samples and billions of cells, even from FFPE, while its spatial portfolio spans Atera In Situ, Xenium In Situ, and Visium Spatial for whole transcriptome insight at subcellular resolution.
Newer additions like Flex Apex and Atera push sample access and throughput further still, profiling FFPE and fixed whole blood and running up to 800 whole transcriptome samples per year. This work powers breakthroughs across pharma, oncology, immunology, and AI cell models, and has been cited in over 10,000 publications by scientists advancing their research worldwide.
